Peer-influenced content. Sources you trust. No registration required. This is HCN.

ACS Risk Biomarkers Significantly Increase After mRNA COVID-19 Vaccine

This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form